drive sale ep despit tougher fx
share gain robot growth suggest increas competit resist
mako yet materi syk faster expect ww selling-day-adjust
ortho implant sale growth vs estimate drove greater share gain
includ share us knee assum snn deliv
project week well know whether syk addit gain came
snn well howev base syk result acceler
robot growth suggest sign held back new robot surgeri competit
reiter outperform rate rais tp
new robot sale acceler buck typic season beat
estim system place new robot us
estim ou placement includ four new system japan
mako total knee procedur us knee sale strong
ex extra sell day vs estim market growth
syk instal base robot surgeri system track exceed ww year-
end approach us increas nearli estim
organ growth vs cse guidanc rais report sale
bil mil vs cse driven strength ortho medic neurotech partial
off-set instrument spine ep estim
factset con includ hit tougher fx vs cse
rais estim target price weve rais organ growth estim
line management guidanc higher-end rang
rais organ growth project averag
weve rais ep follow three year
valuat tp base ev/ebitda multipl unch
project ebitda bil bil risk integr acquisit
product delay failur reach lt goal chang robot surgeri market
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
price
stryker corp global manufactur provid medic devic
equip treatment musculoskelet spinal disord
trauma neurosurgeri endoscopi gener surgeri patient care
one-year valuat scenario base
ev/ebitda ebitda
scenario base high-growth segment grow
growth grow
one-year valuat grey scenario base
ev/ebitda grey ebitda grey
scenario base high-growth segment grow
growth grow
 close
addit detail takeaway
figur analysi selling-day-adjust ortho market perform show greater share gain
us knee implant growth adjust estim mil robot sale report compani knee sale line
ortho bil mil y/i cc vs
sale cc organ driven strong knee perform well
mako tka demand knee cc mil hip strong
mil extra sell day quarter
knee mil mil y/i cc vs
us knee sale mil mil increas ou knee sale mil
hip mil mil y/i cc vs
us hip sale mil mil increas ou hip sale mil mil
trauma extrem mil mil y/i
us trauma extrem sale mil mil increas ou trauma
extrem sale mil mil increas cc growth quarter driven
alpha tibial nail system dd growth foot ankl shoulder product
mil mil y/i cc vs
us sale mil mil increas ou sale mil
mil flat cc
mako place robot ww robot estim vs robot
us compani place robot quarter vs last year ww basi
compani robot instal y/i y/i
mako total knee procedur y/i total mako
procedur mako total hip procedur continu gener rapid growth gain share
y/i estim hip total mako procedur
medsurg bil mil y/i cc
sale cc organ ou medsurg cc
strength japan emerg market europ canada
instrument mil mil y/i cc
us instrument sale mil mil increas ou instrument sale
mil mil increas cc instrument sale slow strong
manag expect instrument deliv above-market growth
endoscopi mil mil y/i cc
us endoscopi sale mil mil increas ou endoscopi sale
mil mil increas cc compani launch camera
manag continu see strong momentum
medic mil mil y/i cc
sale mil mil increas sale mil
mil increas cc due strong perform bed stretcher
well physio portion emerg care busi
sustain mil mil y/i cc
vs cse
us sustain sale mil mil increas
neurotech spine mil in-lin y/i
sale cc organ driven strong demand
neurotech intervent spine partial off-set slower core spine sale strong ou
growth cc partial off-set soft legaci spine perform
neurotech mil mil y/i
us neurotech sale mil mil increas ou neurotech sale
mil mil increas cc reflect strength hemorrhag ischem stroke
product neuro-pow instrument partial off-set softer demand cmf
spine mil mil y/i cc vs
us spine sale mil mil increas ou spine sale mil in-
line increas cc manag cite sale soft price eros cross-
sell scale rep full inventori avail take longer expect
manag see lsd spine growth
 oper margin bp estim
bottom line sale net cog off-set lower sg non-op incom
lower tax deliv ep estim gross margin
bp estim bp last year quarter
gm impact price mix compani expect gm improv price
quarter headwind vs prior year fx unfavor impact
estimate bpop bpnon-op bpnet chg y/i charl martineau pm univers toronto octob
compani expect organ sale growth higher-end
rang manag rais bottom-end ep guidanc
compani expect neg fx impact compani expect
ep sell day differ vs last year
salesy/i chg cc cg org cg salesy/i chg cc cg org estimate varianc charl martineau pm univers toronto octob
chang model
weve rais organ growth estim line management
guidanc higher-end rang rais organ growth project
averag weve rais ep
follow three year
figur chang model
compani mention price
matt miksic vik chopra certifi respect compani secur individu analyz view express
report accur reflect person view subject compani secur part
compens directli indirectli relat specif recommend view express report
